INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:09 am EST
Share
iNtRON Biotechnology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 0.1788 million compared to KRW 0.35353 million a year ago. Net loss was KRW 2,591.9 million compared to KRW 1,683.58 million a year ago. Basic loss per share from continuing operations was KRW 78 compared to KRW 50 a year ago. Diluted loss per share from continuing operations was KRW 78 compared to diluted earnings per share from continuing operations of KRW 18 a year ago. Basic loss per share was KRW 78 compared to KRW 50 a year ago. Diluted loss per share was KRW 22 compared to diluted earnings per share of KRW 18 a year ago.
For the nine months, sales was KRW 0.77282 million compared to KRW 1.37 million a year ago. Net loss was KRW 5,992.61 million compared to net income of KRW 9,279.29 million a year ago. Basic loss per share from continuing operations was KRW 181 compared to basic earnings per share from continuing operations of KRW 273 a year ago. Diluted loss per share from continuing operations was KRW 181 compared to diluted earnings per share from continuing operations of KRW 73 a year ago. Basic loss per share was KRW 181 compared to basic earnings per share of KRW 273 a year ago. Diluted loss per share was KRW 30 compared to diluted earnings per share of KRW 73 a year ago.
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
INTRON BIOTECHNOLOGY, INC. 
